Table 3.
Commercial database analyses of select tumor cell–associated markers in resected GBM from younger and older adult human patients.
| Feature | A Positive (Age <65) | A Negative (Age <65) | A Positive (Age ≥65) | A Negative (Age ≥65) | A P value | B Positive (Age <65) | B Negative (Age <65) | B Positive (Age ≥65) | B Negative (Age ≥65) | B P value | Significant datasets |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MGMT-Me | 283 (34.13%) | 546 (65.87%) | 277 (49.73%) | 280 (50.27%) | 6.63E-09 | N/A | N/A | N/A | N/A | N/A | 1 |
| IHC PD-L1 | 176 (21.54%) | 641 (78.46%) | 98 (17.82%) | 452 (82.18%) | 0.092 | 57 (20.0%) | 230 (80.0%) | 41 (21.0%) | 152 (79.0%) | 0.712 | 0 |
| dMMR/MSI-H | 7 (0.78%) | 895 (99.22%) | 8 (1.51%) | 522 (98.49%) | 0.188 | 11 (0.9%) | 882 (99.1%) | 1 (0.2%) | 483 (99.8%) | 0.067 | 0 |
| CDK6 amplification | 8 (0.89%) | 890 (99.11%) | 9 (1.70%) | 519 (98.30%) | 0.172 | 11 (1.2%) | 904 (98.8%) | 1 (0.2%) | 494 (99.8%) | 0.067 | 0 |
| EGFR amplification | 324 (36.04%) | 575 (63.96%) | 182 (34.47%) | 346 (65.53%) | 0.549 | 267 (29.0%) | 648 (71.0%) | 151 (31.0%) | 344 (69.0%) | 0.603 | 0 |
| NGS-EGFR | 167 (18.56%) | 733 (81.44%) | 81 (15.31%) | 448 (84.69%) | 0.118 | 110 (12.0%) | 805 (88.0%) | 65 (13.0%) | 430 (87.0%) | 0.546 | 0 |
| EGFRvIII mutations | 197 (21.86%) | 704 (78.14%) | 104 (19.62%) | 426 (80.38%) | 0.315 (RNA-seq) | 87 (9.5%) | 828 (90.0%) | 44 (8.9%) | 451 (91.0%) | 0.702 (DNAseq) | 0 |
| EGFR Fusion | 11 (1.24%) | 874 (98.76%) | 4 (0.76%) | 520 (99.23%) | 0.397 | 45 (4.9%) | 870 (95.0%) | 23 (4.6%) | 472 (95.0%) | 0.820 | 0 |
| MET Fusion | 11 (1.22%) | 890 (98.78%) | 8 (1.51%) | 520 (98.48%) | 0.639 | 0 (0.0%) | 915 (100%) | 0 (0.0% | 495 (100%) | N/A | 0 |
| NGS-TERT | 662 (77.07%) | 197 (22.93%) | 473 (82.55%) | 100 (17.45%) | 0.012 | 452 (49.0%) | 463 (51.0%) | 288 (58.0%) | 207 (42.0%) | 0.002 | 2 |
| NGS-PTEN | 252 (30.39%) | 577 (69.61%) | 198 (35.23%) | 364 (64.77%) | 0.059 | 261 (29.0% | 654 (71.0%) | 144 (29.0%) | 351 (71.0%) | 0.823 | 0 |
| NGS-TP53 | 258 (28.67%) | 642 (71.33%) | 170 (32.14%) | 359 (67.86%) | 0.167 | 170 (19.0%) | 745 (81.0%) | 77 (16.0%) | 418 (84.0%) | 0.154 | 0 |
| NGS-NF1 | 131 (14.57%) | 768 (85.43%) | 79 (14.96%) | 449 (85.04% | 0.841 | 99 (11.0%) | 816 (89.0%) | 59 (12.0%) | 436 (88.0%) | 0.532 | 0 |
Data from Caris Life Sciences (Database A) and Tempus (Database B) for DNA expression, amplification, mutations, fusion events, and PD-L1 protein detection as stratified by <65 or ≥65 years of age. Significance, or lack thereof, for each data point across both datasets is included in the final column. NGS was used to detect mutations.